Anais do II Congresso Nacional Acadêmico de Dermatologia
##plugins.themes.bootstrap3.article.sidebar##
Publicado
Nov 18, 2022
##plugins.themes.bootstrap3.article.main##
Resumo
DOI: https://doi.org/10.25248/anais.e11654.2022
O II Congresso Nacional Acadêmico de Dermatologia é uma idealização de eventos anteriores realizados pela Liga de Dermatologia Clínica e Cirúrgica (LADECC), vinculada à Faculdade de Ciências Médicas de Minas Gerais, que conta com o apoio da Sociedade Brasileira de Dermatologia da regional Minas Gerais (SBD-MG).
O intuito é fornecer um encontro extraclasse para a exposição de temas relevantes, inovadores e mais aprofundados em Dermatologia, para acadêmicos de Medicina por todo o Brasil. Além disso, objetiva facilitar o acesso de acadêmicos a publicações científicas de qualidade, uma vez que tem sido uma demanda cada vez maior por parte dos acadêmicos de Medicina.
O evento conta com a participação de ligas de todo o país, promovendo o debate científico e troca de informações entre diversos estados, com palestras de dermatologistas renomados no país, com a apresentação de pôsteres e discussões de casos clínicos para enriquecer ainda mais o debate no congresso. Ademais, oferecemos a oportunidade de publicação dos resumos na forma de Anais de Congresso da Revista Acervo Médico Indexada do grupo Acervo Mais Revistas.
Por meio dessa integração, possibilitamos relações e contatos de acadêmicos e profissionais com o mesmo interesse e/ou paixão: a Dermatologia!
O evento ocorrerá dia 19 de novembro de 2022, das 8:00 às 17:30, de forma online na plataforma da VEM Events.
Comissão do evento
Científico
Amanda Cambraia Ferreira
Ana Carolina Wegmann Villela
Ana Elisa Barreto Calixto
Mariana Almeida Botelho
Júlia Bernardes de Freire Lopes
Marketing
Izabela Silveira Amédée Péret
Tiago Guedes de Oliveira Viana
Lara Halberstadt Beskow
Patrocínio
Júlia Mendes e Parreiras Gomes
Luiza Fernanda Machado de Vasconcelos
Gabriel Macedo Malta Santos
Coordenação geral
Lívia Amaral Salomé Furtado
Comunicação
Caíque Gonzaga Pedrette de Oliveira
Milena Souza Lopes
Rebeca Morais Santos de Rezende
Bruna Vivian Antunes Campos
Camila Rayane Barbosa de Sousa
Estrutural
Beatriz Lopes Bessa
Nathália Paim Morais
Maria Fernanda Velloso Kavadi
Matheus Augusto Coelho Quitete
Luisa De Sousa Mattos Murta
Presidência
Luísa Tavares de Azevedo
Vice-presidência
Geórgia de Lima Vieira Carneiro
Presidente discente
Soraya Neves Marques Barbosa dos Santos
Vice-presidente discente
Carolina de Magalhães Ledsham Lopes
##plugins.themes.bootstrap3.article.details##
Como Citar
Anais do II Congresso Nacional Acadêmico de Dermatologia. (2022). Revista Eletrônica Acervo Médico, 21, e11654. Recuperado de https://acervomais.com.br/index.php/medico/article/view/11654
Edição
Seção
Anais de Evento Científico
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
1. DE CAROLIS E, et al. Old and New Insights into Sporothrix schenckii. Complex Biology and Identification. Pathogens, 2022; 11(3): 297.
2. LOPES-BEZERRA LM, et al. Sporotrichosis between 1898 and 2017: The evolution of knowledge on a changeable disease and on emerging etiological agents. Medical mycology, 2018; 56(1): 126–143.
3. POESTER VR, et al. Treatment of Human Sporotrichosis Caused by Sporothrix brasiliensis. Journal of Fungi, 2022; 8(1): 70.
4. SCHECHTMAN RC, et al. Sporotrichosis: hyperendemic by zoonotic transmission, with atypical presentations, hypersensitivity reactions and greater severity. Anais Brasileiros de Dermatologia, 2022; 97(1): 1-13.
5. XAVIER JRB, et al. Human sporotrichosis outbreak caused by Sporothrix brasiliensis in a veterinary hospital in Southern Brazil. Journal of Medical Mycology, 2021; 31(3): 101163.
1. BORGES JC, et al. Atual cenário da tuberculose no Brasil: medidas de identificação, tratamento e prevenção da doença. Revista Eletrônica Acervo Saúde, 2018; (7): S341-S346
2. KHADKA P, et al. Cutaneous Tuberculosis: Clinicopathologic Arrays and Diagnostic Challenges. Dermatology Research and Practice, 2018; 1-9.
3. MANN D, et al. Cutaneous tuberculosis in Rio de Janeiro, Brazil: description of a series of 75 cases. International Journal of Dermatology, 2019; 58: 1451-1459.
4. MENEGHETI GG, et al. Reação em cadeia da polimerase como determinante para o diagnóstico de tuberculose cutânea. Rev Soc Bras Clin Med, 2018; 16(2): 116-118
5. PORTO HLS, et al. Lupus Vulgaris: A Diagnostic Challenge. Journal of the Portuguese Society of Dermatology and Venereology, 2021; 79(1): 75-77.
1. CHARLTON OA, et al. Toxic Epidermal Necrolysis and Steven–Johnson Syndrome: A Comprehensive Review. Adv Wound Care (New Rochelle), 2020; 9(7): 426-439.
2. FRANTZ R, et al. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas), 2021;57(9):2-15.
3. MEDEIROS MP, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis - retrospective review of cases in a high complexity hospital in Brazil. Int J Dermatol, 2020;59(2), 191–196.
4. NOE MH e MICHELETTI RG. Diagnosis and Management of Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. Clin Dermatol, 2020; 38(6): 607-612.
5. ZHANG AJ, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. Int J Dermatol, 2019; 58(9): 1069–1077.
1. CASTILLO RL e FEMIA AN. Covert clues: the non-hallmark cutaneous manifestations of dermatomyositis. Annals of Translational Medicine, 2021; 9(5).
2. MAINETTI C, et al. Cutaneous manifestations of dermatomyositis: a comprehensive review. Clinical reviews in allergy & immunology, 2017; 53(3): 337-356.
3. MIYASHIRO D, et al. Extensive cutaneous involvement by dermatomyositis: Report of six cases and review of the literature. Autoimmunity Reviews, 2020; 19(12): 102680.
4. OKIYAMA N. Clinical features and cutaneous manifestations of juvenile and adult patients of dermatomyositis associated with myositis-specific autoantibodies. Journal of Clinical Medicine, 2021; 10(8): 1725.
1. BEHERA SK, et al. DRESS syndrome: a detailed insight. Hosp Pract, 2018; 46(3): 152-162.
2. CABAÑAS R, et al. Spanish Guidelines for Diagnosis, Management, Treatment, and Prevention of DRESS Syndrome. J Investig Allergol Clin Immunol, 2020; 30(4): 229-253.
3. CARDONES AR. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clin Dermatol, 2020; 38(6): 702-711.
4. MARTÍNEZ-CABRIALES SA, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): How Far Have We Come? Am J Clin Dermatol, 2019; 20(2): 217-236.
5. SHIOHARA T e MIZUKAWA Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int, 2019; 68(3): 301-308.
1. AKSOY H, et al. COVID-19 induced telogen effluvium. Dermatologic Therapy, 2021; 34: e15175.
2. CLINE A, et al. A surge in the incidence of Telogen effluvium in minority predominant communities heavily impacted by COVID-19. J Am Acad Dermatol., 2020; 4(3): 773-775.
3. HUSSAIN N, et al. A systematic review of acute telogen effluvium, a harrowing post COVID-19 manifestation. Journal of Medical Virology, 2022; 94: 1391–1401.
4. KUTLU Ö e METIN A. Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of the COVID-19 pandemic. Dermatol Ther., 2020; 33(6): e14096.
5. OLDS H, et al. Telogen effluvium associated with COVID-19. Dermatol Ther; 2021 34(2): e14761.
6. SEYF S, et al. Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity. Journal of Medicine and Life, 2022; 15(5).
1. LI SC. Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis. Pediatric Clinics, 2018; 65 (4): 757-781.
2. ZHAO M, et al. Clinical treatment options in scleroderma: recommendations and comprehensive review. Clinical Reviews in Allergy & Immunology, 2021; p. 1-19.
3. ZULIAN F e TIRELLI F. Treatment in juvenile scleroderma. Current Rheumatology Reports, 2020; 22 (8): 1-9.
1. RAMOS PM, et al. Consenso sobre tratamento da alopecia areata. Sociedade Brasileira de Dermatologia. Anais Brasileiros de Dermatologia, 2020; 95: 39-52.
2. SIMAKOU T, et al. Alopecia areata: A multifactorial autoimmune condition. Journal of autoimmunity, 2019; 98: 74-85.
3. STRAZZULLA LC, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. Journal of the American Academy of Dermatology, 2018; 78(1): 15-24.
4. ZHENG C, et al. Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors. Dermatol Clin., 2021; 39(3): 407-415.
1. EMILIO CR. Comparação da eficácia do ácido 5-aminolevulínico com a se seu metil éster utilizando-se a terapia fotodinâmica no tratamento do carcinoma espinocelular felino. Tese (Doutorado em Ciências na Área de Tecnologia Nuclear – Materiais) - Instituto de pesquisas energéticas e nucleares. Autarquia Associada à Universidade de São Paulo (USP), São Paulo, 2008; 127 p.
2. HEERFORDT IM, et al. Bringing the gentle properties of daylight photodynamic therapy indoors: A systematic review of efficacy and safety. Photodiagnosis Photodyn Ther., 2022; 39: 102858.
3. OKHOVAT JP, et al. Comparison of the Safety and Efficacy of Daylight Photodynamic Therapy and Conventional Photodynamic Therapy for Actinic Keratoses: A Systematic Review Demonstrating Noninferiority. Journal of the American Academy of Dermatology, 2022; 86(6): 1444–46.
4. TOMÁS-VELÁZQUEZ AP e REDONDO P. Switching From Conventional Photodynamic Therapy to Daylight Photodynamic Therapy For Actinic Keratoses: Systematic Review and Meta-Analysis. Actas Dermo-Sifiliográficas, 2017; 108(4): 282–92.
1. COSTA MK, et al. Artigo de Revisão: Novas Opções de Tratamento no Melanoma Metastático. Revista de Patologia do Tocantins, 2018; 5(2): 58-66.
2. FARIES BM. Intralesional Immunotherapy for Metastatic Melanoma. The Oldest and Newest Treatment in Oncology. Revista Oncology, 2017; 1-2(21): 65-73.
3. RALLI M, et al. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. Journal of immunology research, 2020: 9235638.
1. DILLON KL, et al. A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata. Clinical, Cosmetic and Investigational Dermatology, 2021; 25(6): 691-714
2. KING B, et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. The New England Journal of Medicine, 2022; 5(5): 1687-1699.
3. STERKENS A, et al. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. Clinical and Experimental Medicine, 2021; 21(2): 215–230.
4. WANG E, et al. JAK Inhibitors for Treatment of Alopecia Areata. The Journal of investigative dermatology, 2018; 138(9): 1911–1916.
1. AZAMBUJA RD. The need of dermatologists, psychiatrists and psychologists joint care in psychodermatology. Anais brasileiros de dermatologia, 2017; 92: 63-71.
2. DE SOUZA IH, et al. Psicodermatoses: uma análise dos aspectos fisiopatológicos, sociais e dos tratamentos multidisciplinares. Revista Eletrônica Acervo Científico, 2020; 16: e5552.
3. EGEBERG A, et al. Risk of first‐time and recurrent depression in patients with psoriasis: a population‐based cohortstudy. British Journal of Dermatology, 2019; 180(1): 116-121.
4. HUANG Y, et al. Association of Chronic Spontaneous Urticaria With Anxiety and Depression in Adolescents: A Mediation Analysis. Frontiers in Psychiatry, 2021; 1447.
5. WEBER MB, et al. Use of psychiatric drugs in Dermatology. Anais Brasileiros de Dermatologia, 2020; 95: 133-143.
1. FOOD AND DRUG ADMINISTRATION (FDA). FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older. 2022.
2. QI F, et al. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. Revista Eletrônica Front Immunol., 2021; 12:790125.
3. ROSMARIN D, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. The Lancet, 2020; 396: 110-120.
4. WHITE C e MILLER R. A Literature Review Investigating the Use of Topical Janus Kinase Inhibitors for the Treatment of Vitiligo. Revista Eletrônica J Clin Aesthet Dermatol., 2022; 15(4): 20-25.
1. BITTNER GC, et al. Tolkachjov, Mohs micrographic surgery: a review of indications, technique, outcomes, and considerations, Anais Brasileiros de Dermatologia, 2021; 96(3): 263-277.
2. CHEN ELA, et al. Mohs Micrographic Surgery: Development, Technique, and Applications in Cutaneous Malignancies. Semin Plast Surg., 2018; 32(2): 60-68.
3. ETZKORN JR e ALAM M. What Is Mohs Surgery? JAMA Dermatol., 2020; 156(6): 716.
4. PRICKETT KA e RAMSEY ML. Mohs Micrographic Surgery. StatPearls Publishing, 2022.
1. ARLETTE J, et al. Ultrasound for Soft Tissue Filler Facial Rejuvenation. Ultrasound for Soft Tissue Filler Facial Rejuvenation. Journal of cutaneous medicine and surgery, 2021; 25(4): 456-457.
2. LEVY J, et al. High-frequency ultrasound in clinical dermatology: a review. The Ultrasound Journal, 2021; 13(1): 24.
3. SCHELKE LW, et al. Ultrasound to improve the safety of hyaluronic acid filler treatments. Journal of cosmetic dermatology, 2018; 17(6): 1019–1024.
4. URDIALES-GÁLVEZ F, et al. Ultrasound patterns of different dermal filler materials used in aesthetics. Journal of cosmetic dermatology, 2021; 20(5): 1541–1548.
5. WORTSMAN X. Practical applications of ultrasound in dermatology. Clinics in dermatology, 2021; 39(4): 605–623.
1. AVALLONE G, et al. SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review. Int J Dermatol., 2022; 61(10): 1187-1204.
2. BURLANDO M, et al. Cutaneous reactions to COVID-19 vaccine at the dermatology primary care. Immun Inflamm Dis., 2022; 10(2): 265-271.
3. GREENHAWT M, et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. The Journal of Allergy and Clinical Immunology. In Practice, 2021; 9: 10.
4. SHAKOEI S, et al. Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases. Dermatol Ther., 2022; 35(8): e15651.
5. SUN Q, et al. COVID-19 Vaccines and the Skin: The Landscape of Cutaneous Vaccine Reactions Worldwide. Dermatol Clin., 2021; 39(4): 653-673.
1. ANGELES CV e SABEL MS. Immunotherapy for Merkel cell carcinoma. J Surg Oncol., 2021; 123: 775– 781.
2. LYDOLPH W, et al. Advances in Immunology: A Cornerstone in Diagnosis and Therapy of Merkel Cell Carcinoma. Journal of Investigative Medicine High Impact Case Reports, 2022; 10: 23247096221089492.
3. O’BRIEN T e POWER DG. Metastatic Merkel-cell carcinoma: the dawn of a new era. Case Reports, 2018; 2018: bcr-2018- 224924.
4. ROBINSON CG, et al. Recent advances in Merkel cell carcinoma. F1000Research, 2019; 8(F1000 Faculty Rev): 1995.
5. RUBIN KM, et al. Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma. Seminars in Oncology Nursing, 2019; 35(5): 150924.
1. BITTNER G, et al. Cirurgia micrográfica de Mohs: revisão de indicações, técnica, resultados e considerações. Anais Brasileiros de Dermatologia, 2020; 96(3): 263-277.
2. CERCI F, et al. Comparação entre os subtipos de carcinomas basocelulares observados na biópsia pré-operatória e na cirurgia micrográfica de Mohs. Anais Brasileiros de Dermatologia, 2020; 95(5): 594-601.
3. ISHIZUKI S e NAKAMURA Y. Evidence from Clinical Studies Related to Dermatologic Surgeries for Skin Cancer. Cancers (Basel), 2022; 8(14): 3835.
4. SANTOS MF, et al. Predictive factors for the highest number of stages in Mohs surgery: a study of 256 cases. Surgical & Cosmetic Dermatology, 2020; 12(4): 332-338.
1. BRASIL. Comissão Nacional de Incorporação de Tecnologias no SUS. Adalimumabe, etanercepte, infliximabe, secuquinumabe e ustequinumabe para psoríase moderada a grave. 2018. Disponível em: https://www.sbd.org.br/mm/cms/2018/05/25/relatoriomedicamentosbiologicospsoriasecp262018.pdf. Acessado em: 2 de agosto de 2022.
2. GONZÁLEZ-PARRA S e DAUDÉN E. Psoriasis y depresión: el papel de la inflamación. Actas Dermo-Sifiliográficas, 2019; 110(1): 12-19.
3. HÖLSKEN S, et al. Common Fundamentals of Psoriasis and Depression. Acta Dermato-Venereologica, 2021; 101(11): adv00609.
4. PATEL N, et al. Psoriasis, Depression and Inflammatory Overlap: A Review. American Journal of Clinical Dermatology, 2017; 18(5): 613-620.
5. RUA MO, et al. Influências da depressão na psoríase: uma relação bidirecional. Revista Eletrônica Acervo Científico, 2021; 23: e5650.
6. TRIBÓ MJ, et al. Patients with Moderate to Severe Psoriasis Associate with Higher Risk of Depression and Anxiety Symptoms: Results of a Multivariate Study of 300 Spanish Individuals with Psoriasis. Acta Dermato-Venereologica, 2019; 99(4): 417-422.
1. KALIL CLPV, et al. Uso dos probióticos em dermatologia. Surgical & Cosmetic Dermatology, 2020; 12: 3.
2. MACHADO CRF. Novas abordagens terapêuticas na dermatite atópica. Repositório Institucional da Universidade Fernando Pessoa (Dissertação Mestrado), 2018; 68p.
3. NOLÊTO AGL, et al. O uso de probióticos na dermatologia. Brazilian Journal of Health Review, 2021; 4: 27721- 27779.
4. RAVANHANE BR, et al. Probióticos podem ser uma alternativa no tratamento da dermatite atópica em adultos? BWS Journal, 2020; 5.
1. CEBECI D, et al. The Effect of Personal Protective Equipment (PPE) and Disinfectants on Skin Health During Covid 19 Pandemia. Medical Archives, 2021; 75(5): 361-365.
2. DARLENSKI R, et al. Prevention and occupational hazards for the skin during COVID-19 pandemic. Clinics in Dermatology, 2021; 39(1): 92-97.
3. DAYE M, et al. Evaluation of skin problems and dermatology life quality index in health care workers who use personal protection measures during COVID-19 pandemic. Dermatologic Therapy, 2020; 33(6): e14346.
4. GASPARINO R, et al. Prophylactic dressings in the prevention of pressure ulcer related to the use of personal protective equipment by health professional facing the COVID-19 pandemic: A randomized clinical trial. Wound Repair and Regeneration, 2021; 29(1): 183-188.
5. HU H, et al. The adverse skin reactions of health care workers using personal protective equipment for COVID-19. Medicine, 2020; 99(24): e20603.
1. AUTIER P e DORÉ JF. Influence of sun exposures during childhood and during adulthood on melanoma risk. International journal of cancer, Estados Unidos da América, 1999; 77(4): 533-537.
2. DAVIS L, et al. Current state of melanoma diagnosis and treatment. Cancer biology & therapy, 2019; 20(11): 1366–1379.
3. DIMATOS D, et al. Melanoma cutâneo no brasil. Arquivos Catarinenses de Medicina, 2009; 38: 14-19.
4. SAGINALA K, et al. Epidemiology of Melanoma. Medical Sciences, 2021; 9(4): 63.
5. VERONESE L e MARQUES M. Critérios anatomopatológicos para melanoma maligno cutâneo: análise qualitativa de sua eficácia e revisão da literatura. Jornal Brasileiro de Patologia e Medicina Laboratorial, 2004; 40: 2.
2. LOPES-BEZERRA LM, et al. Sporotrichosis between 1898 and 2017: The evolution of knowledge on a changeable disease and on emerging etiological agents. Medical mycology, 2018; 56(1): 126–143.
3. POESTER VR, et al. Treatment of Human Sporotrichosis Caused by Sporothrix brasiliensis. Journal of Fungi, 2022; 8(1): 70.
4. SCHECHTMAN RC, et al. Sporotrichosis: hyperendemic by zoonotic transmission, with atypical presentations, hypersensitivity reactions and greater severity. Anais Brasileiros de Dermatologia, 2022; 97(1): 1-13.
5. XAVIER JRB, et al. Human sporotrichosis outbreak caused by Sporothrix brasiliensis in a veterinary hospital in Southern Brazil. Journal of Medical Mycology, 2021; 31(3): 101163.
1. BORGES JC, et al. Atual cenário da tuberculose no Brasil: medidas de identificação, tratamento e prevenção da doença. Revista Eletrônica Acervo Saúde, 2018; (7): S341-S346
2. KHADKA P, et al. Cutaneous Tuberculosis: Clinicopathologic Arrays and Diagnostic Challenges. Dermatology Research and Practice, 2018; 1-9.
3. MANN D, et al. Cutaneous tuberculosis in Rio de Janeiro, Brazil: description of a series of 75 cases. International Journal of Dermatology, 2019; 58: 1451-1459.
4. MENEGHETI GG, et al. Reação em cadeia da polimerase como determinante para o diagnóstico de tuberculose cutânea. Rev Soc Bras Clin Med, 2018; 16(2): 116-118
5. PORTO HLS, et al. Lupus Vulgaris: A Diagnostic Challenge. Journal of the Portuguese Society of Dermatology and Venereology, 2021; 79(1): 75-77.
1. CHARLTON OA, et al. Toxic Epidermal Necrolysis and Steven–Johnson Syndrome: A Comprehensive Review. Adv Wound Care (New Rochelle), 2020; 9(7): 426-439.
2. FRANTZ R, et al. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas), 2021;57(9):2-15.
3. MEDEIROS MP, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis - retrospective review of cases in a high complexity hospital in Brazil. Int J Dermatol, 2020;59(2), 191–196.
4. NOE MH e MICHELETTI RG. Diagnosis and Management of Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. Clin Dermatol, 2020; 38(6): 607-612.
5. ZHANG AJ, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. Int J Dermatol, 2019; 58(9): 1069–1077.
1. CASTILLO RL e FEMIA AN. Covert clues: the non-hallmark cutaneous manifestations of dermatomyositis. Annals of Translational Medicine, 2021; 9(5).
2. MAINETTI C, et al. Cutaneous manifestations of dermatomyositis: a comprehensive review. Clinical reviews in allergy & immunology, 2017; 53(3): 337-356.
3. MIYASHIRO D, et al. Extensive cutaneous involvement by dermatomyositis: Report of six cases and review of the literature. Autoimmunity Reviews, 2020; 19(12): 102680.
4. OKIYAMA N. Clinical features and cutaneous manifestations of juvenile and adult patients of dermatomyositis associated with myositis-specific autoantibodies. Journal of Clinical Medicine, 2021; 10(8): 1725.
1. BEHERA SK, et al. DRESS syndrome: a detailed insight. Hosp Pract, 2018; 46(3): 152-162.
2. CABAÑAS R, et al. Spanish Guidelines for Diagnosis, Management, Treatment, and Prevention of DRESS Syndrome. J Investig Allergol Clin Immunol, 2020; 30(4): 229-253.
3. CARDONES AR. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clin Dermatol, 2020; 38(6): 702-711.
4. MARTÍNEZ-CABRIALES SA, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): How Far Have We Come? Am J Clin Dermatol, 2019; 20(2): 217-236.
5. SHIOHARA T e MIZUKAWA Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int, 2019; 68(3): 301-308.
1. AKSOY H, et al. COVID-19 induced telogen effluvium. Dermatologic Therapy, 2021; 34: e15175.
2. CLINE A, et al. A surge in the incidence of Telogen effluvium in minority predominant communities heavily impacted by COVID-19. J Am Acad Dermatol., 2020; 4(3): 773-775.
3. HUSSAIN N, et al. A systematic review of acute telogen effluvium, a harrowing post COVID-19 manifestation. Journal of Medical Virology, 2022; 94: 1391–1401.
4. KUTLU Ö e METIN A. Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of the COVID-19 pandemic. Dermatol Ther., 2020; 33(6): e14096.
5. OLDS H, et al. Telogen effluvium associated with COVID-19. Dermatol Ther; 2021 34(2): e14761.
6. SEYF S, et al. Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity. Journal of Medicine and Life, 2022; 15(5).
1. LI SC. Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis. Pediatric Clinics, 2018; 65 (4): 757-781.
2. ZHAO M, et al. Clinical treatment options in scleroderma: recommendations and comprehensive review. Clinical Reviews in Allergy & Immunology, 2021; p. 1-19.
3. ZULIAN F e TIRELLI F. Treatment in juvenile scleroderma. Current Rheumatology Reports, 2020; 22 (8): 1-9.
1. RAMOS PM, et al. Consenso sobre tratamento da alopecia areata. Sociedade Brasileira de Dermatologia. Anais Brasileiros de Dermatologia, 2020; 95: 39-52.
2. SIMAKOU T, et al. Alopecia areata: A multifactorial autoimmune condition. Journal of autoimmunity, 2019; 98: 74-85.
3. STRAZZULLA LC, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. Journal of the American Academy of Dermatology, 2018; 78(1): 15-24.
4. ZHENG C, et al. Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors. Dermatol Clin., 2021; 39(3): 407-415.
1. EMILIO CR. Comparação da eficácia do ácido 5-aminolevulínico com a se seu metil éster utilizando-se a terapia fotodinâmica no tratamento do carcinoma espinocelular felino. Tese (Doutorado em Ciências na Área de Tecnologia Nuclear – Materiais) - Instituto de pesquisas energéticas e nucleares. Autarquia Associada à Universidade de São Paulo (USP), São Paulo, 2008; 127 p.
2. HEERFORDT IM, et al. Bringing the gentle properties of daylight photodynamic therapy indoors: A systematic review of efficacy and safety. Photodiagnosis Photodyn Ther., 2022; 39: 102858.
3. OKHOVAT JP, et al. Comparison of the Safety and Efficacy of Daylight Photodynamic Therapy and Conventional Photodynamic Therapy for Actinic Keratoses: A Systematic Review Demonstrating Noninferiority. Journal of the American Academy of Dermatology, 2022; 86(6): 1444–46.
4. TOMÁS-VELÁZQUEZ AP e REDONDO P. Switching From Conventional Photodynamic Therapy to Daylight Photodynamic Therapy For Actinic Keratoses: Systematic Review and Meta-Analysis. Actas Dermo-Sifiliográficas, 2017; 108(4): 282–92.
1. COSTA MK, et al. Artigo de Revisão: Novas Opções de Tratamento no Melanoma Metastático. Revista de Patologia do Tocantins, 2018; 5(2): 58-66.
2. FARIES BM. Intralesional Immunotherapy for Metastatic Melanoma. The Oldest and Newest Treatment in Oncology. Revista Oncology, 2017; 1-2(21): 65-73.
3. RALLI M, et al. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. Journal of immunology research, 2020: 9235638.
1. DILLON KL, et al. A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata. Clinical, Cosmetic and Investigational Dermatology, 2021; 25(6): 691-714
2. KING B, et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. The New England Journal of Medicine, 2022; 5(5): 1687-1699.
3. STERKENS A, et al. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. Clinical and Experimental Medicine, 2021; 21(2): 215–230.
4. WANG E, et al. JAK Inhibitors for Treatment of Alopecia Areata. The Journal of investigative dermatology, 2018; 138(9): 1911–1916.
1. AZAMBUJA RD. The need of dermatologists, psychiatrists and psychologists joint care in psychodermatology. Anais brasileiros de dermatologia, 2017; 92: 63-71.
2. DE SOUZA IH, et al. Psicodermatoses: uma análise dos aspectos fisiopatológicos, sociais e dos tratamentos multidisciplinares. Revista Eletrônica Acervo Científico, 2020; 16: e5552.
3. EGEBERG A, et al. Risk of first‐time and recurrent depression in patients with psoriasis: a population‐based cohortstudy. British Journal of Dermatology, 2019; 180(1): 116-121.
4. HUANG Y, et al. Association of Chronic Spontaneous Urticaria With Anxiety and Depression in Adolescents: A Mediation Analysis. Frontiers in Psychiatry, 2021; 1447.
5. WEBER MB, et al. Use of psychiatric drugs in Dermatology. Anais Brasileiros de Dermatologia, 2020; 95: 133-143.
1. FOOD AND DRUG ADMINISTRATION (FDA). FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older. 2022.
2. QI F, et al. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. Revista Eletrônica Front Immunol., 2021; 12:790125.
3. ROSMARIN D, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. The Lancet, 2020; 396: 110-120.
4. WHITE C e MILLER R. A Literature Review Investigating the Use of Topical Janus Kinase Inhibitors for the Treatment of Vitiligo. Revista Eletrônica J Clin Aesthet Dermatol., 2022; 15(4): 20-25.
1. BITTNER GC, et al. Tolkachjov, Mohs micrographic surgery: a review of indications, technique, outcomes, and considerations, Anais Brasileiros de Dermatologia, 2021; 96(3): 263-277.
2. CHEN ELA, et al. Mohs Micrographic Surgery: Development, Technique, and Applications in Cutaneous Malignancies. Semin Plast Surg., 2018; 32(2): 60-68.
3. ETZKORN JR e ALAM M. What Is Mohs Surgery? JAMA Dermatol., 2020; 156(6): 716.
4. PRICKETT KA e RAMSEY ML. Mohs Micrographic Surgery. StatPearls Publishing, 2022.
1. ARLETTE J, et al. Ultrasound for Soft Tissue Filler Facial Rejuvenation. Ultrasound for Soft Tissue Filler Facial Rejuvenation. Journal of cutaneous medicine and surgery, 2021; 25(4): 456-457.
2. LEVY J, et al. High-frequency ultrasound in clinical dermatology: a review. The Ultrasound Journal, 2021; 13(1): 24.
3. SCHELKE LW, et al. Ultrasound to improve the safety of hyaluronic acid filler treatments. Journal of cosmetic dermatology, 2018; 17(6): 1019–1024.
4. URDIALES-GÁLVEZ F, et al. Ultrasound patterns of different dermal filler materials used in aesthetics. Journal of cosmetic dermatology, 2021; 20(5): 1541–1548.
5. WORTSMAN X. Practical applications of ultrasound in dermatology. Clinics in dermatology, 2021; 39(4): 605–623.
1. AVALLONE G, et al. SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review. Int J Dermatol., 2022; 61(10): 1187-1204.
2. BURLANDO M, et al. Cutaneous reactions to COVID-19 vaccine at the dermatology primary care. Immun Inflamm Dis., 2022; 10(2): 265-271.
3. GREENHAWT M, et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. The Journal of Allergy and Clinical Immunology. In Practice, 2021; 9: 10.
4. SHAKOEI S, et al. Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases. Dermatol Ther., 2022; 35(8): e15651.
5. SUN Q, et al. COVID-19 Vaccines and the Skin: The Landscape of Cutaneous Vaccine Reactions Worldwide. Dermatol Clin., 2021; 39(4): 653-673.
1. ANGELES CV e SABEL MS. Immunotherapy for Merkel cell carcinoma. J Surg Oncol., 2021; 123: 775– 781.
2. LYDOLPH W, et al. Advances in Immunology: A Cornerstone in Diagnosis and Therapy of Merkel Cell Carcinoma. Journal of Investigative Medicine High Impact Case Reports, 2022; 10: 23247096221089492.
3. O’BRIEN T e POWER DG. Metastatic Merkel-cell carcinoma: the dawn of a new era. Case Reports, 2018; 2018: bcr-2018- 224924.
4. ROBINSON CG, et al. Recent advances in Merkel cell carcinoma. F1000Research, 2019; 8(F1000 Faculty Rev): 1995.
5. RUBIN KM, et al. Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma. Seminars in Oncology Nursing, 2019; 35(5): 150924.
1. BITTNER G, et al. Cirurgia micrográfica de Mohs: revisão de indicações, técnica, resultados e considerações. Anais Brasileiros de Dermatologia, 2020; 96(3): 263-277.
2. CERCI F, et al. Comparação entre os subtipos de carcinomas basocelulares observados na biópsia pré-operatória e na cirurgia micrográfica de Mohs. Anais Brasileiros de Dermatologia, 2020; 95(5): 594-601.
3. ISHIZUKI S e NAKAMURA Y. Evidence from Clinical Studies Related to Dermatologic Surgeries for Skin Cancer. Cancers (Basel), 2022; 8(14): 3835.
4. SANTOS MF, et al. Predictive factors for the highest number of stages in Mohs surgery: a study of 256 cases. Surgical & Cosmetic Dermatology, 2020; 12(4): 332-338.
1. BRASIL. Comissão Nacional de Incorporação de Tecnologias no SUS. Adalimumabe, etanercepte, infliximabe, secuquinumabe e ustequinumabe para psoríase moderada a grave. 2018. Disponível em: https://www.sbd.org.br/mm/cms/2018/05/25/relatoriomedicamentosbiologicospsoriasecp262018.pdf. Acessado em: 2 de agosto de 2022.
2. GONZÁLEZ-PARRA S e DAUDÉN E. Psoriasis y depresión: el papel de la inflamación. Actas Dermo-Sifiliográficas, 2019; 110(1): 12-19.
3. HÖLSKEN S, et al. Common Fundamentals of Psoriasis and Depression. Acta Dermato-Venereologica, 2021; 101(11): adv00609.
4. PATEL N, et al. Psoriasis, Depression and Inflammatory Overlap: A Review. American Journal of Clinical Dermatology, 2017; 18(5): 613-620.
5. RUA MO, et al. Influências da depressão na psoríase: uma relação bidirecional. Revista Eletrônica Acervo Científico, 2021; 23: e5650.
6. TRIBÓ MJ, et al. Patients with Moderate to Severe Psoriasis Associate with Higher Risk of Depression and Anxiety Symptoms: Results of a Multivariate Study of 300 Spanish Individuals with Psoriasis. Acta Dermato-Venereologica, 2019; 99(4): 417-422.
1. KALIL CLPV, et al. Uso dos probióticos em dermatologia. Surgical & Cosmetic Dermatology, 2020; 12: 3.
2. MACHADO CRF. Novas abordagens terapêuticas na dermatite atópica. Repositório Institucional da Universidade Fernando Pessoa (Dissertação Mestrado), 2018; 68p.
3. NOLÊTO AGL, et al. O uso de probióticos na dermatologia. Brazilian Journal of Health Review, 2021; 4: 27721- 27779.
4. RAVANHANE BR, et al. Probióticos podem ser uma alternativa no tratamento da dermatite atópica em adultos? BWS Journal, 2020; 5.
1. CEBECI D, et al. The Effect of Personal Protective Equipment (PPE) and Disinfectants on Skin Health During Covid 19 Pandemia. Medical Archives, 2021; 75(5): 361-365.
2. DARLENSKI R, et al. Prevention and occupational hazards for the skin during COVID-19 pandemic. Clinics in Dermatology, 2021; 39(1): 92-97.
3. DAYE M, et al. Evaluation of skin problems and dermatology life quality index in health care workers who use personal protection measures during COVID-19 pandemic. Dermatologic Therapy, 2020; 33(6): e14346.
4. GASPARINO R, et al. Prophylactic dressings in the prevention of pressure ulcer related to the use of personal protective equipment by health professional facing the COVID-19 pandemic: A randomized clinical trial. Wound Repair and Regeneration, 2021; 29(1): 183-188.
5. HU H, et al. The adverse skin reactions of health care workers using personal protective equipment for COVID-19. Medicine, 2020; 99(24): e20603.
1. AUTIER P e DORÉ JF. Influence of sun exposures during childhood and during adulthood on melanoma risk. International journal of cancer, Estados Unidos da América, 1999; 77(4): 533-537.
2. DAVIS L, et al. Current state of melanoma diagnosis and treatment. Cancer biology & therapy, 2019; 20(11): 1366–1379.
3. DIMATOS D, et al. Melanoma cutâneo no brasil. Arquivos Catarinenses de Medicina, 2009; 38: 14-19.
4. SAGINALA K, et al. Epidemiology of Melanoma. Medical Sciences, 2021; 9(4): 63.
5. VERONESE L e MARQUES M. Critérios anatomopatológicos para melanoma maligno cutâneo: análise qualitativa de sua eficácia e revisão da literatura. Jornal Brasileiro de Patologia e Medicina Laboratorial, 2004; 40: 2.